Physician profile
Rupdev Khosa
NPI 1033210497
$1,020.73
in general payments reported to CMS, 2019-2025
12 companies · $162 in 2025
The $162 reported for 2025 was more than what a typical Physical Medicine & Rehabilitation provider received nationally (typical 2025 total: $138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $192 · 2020: $52.33 · 2021: $186 · 2022: $185 · 2023: $96.07 · 2024: $148 · 2025: $162.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $406.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $405.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Fresenius USA Marketing, INC. | $361.84 | 2019-2025 | Velphoro, Velphoro |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $146.23 | 2022 | |
| Janssen Pharmaceuticals, INC | $124.85 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $121.83 | 2025 | Zoryve |
| Bayer Healthcare Pharmaceuticals INC. | $56.46 | 2024 | |
| Astrazeneca Pharmaceuticals Lp | $46.14 | 2019-2021 | |
| Vifor Pharma, INC. | $44.94 | 2019 | |
| Ardelyx, INC. | $31.25 | 2024 | Ibsrela |
| Aurinia Pharma U.S., INC. | $26.12 | 2023 | Lupkynis |
| Otsuka America Pharmaceutical, INC. | $22.84 | 2019 | |
| Amgen INC. | $21.54 | 2019 | |
| Collegium Pharmaceutical, INC. | $16.69 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rupdev Khosa listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.